Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,582 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J. Baraliakos X, et al. Among authors: sorensen h. Arthritis Res Ther. 2005;7(3):R439-44. doi: 10.1186/ar1693. Epub 2005 Feb 21. Arthritis Res Ther. 2005. PMID: 15899030 Free PMC article. Clinical Trial.
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J. Baraliakos X, et al. Among authors: sorensen h. J Rheumatol. 2007 Mar;34(3):510-5. Epub 2007 Feb 1. J Rheumatol. 2007. PMID: 17299842 Clinical Trial.
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.
Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J. Baraliakos X, et al. Among authors: sorensen h. Rheumatology (Oxford). 2011 Sep;50(9):1690-9. doi: 10.1093/rheumatology/ker194. Epub 2011 Jun 14. Rheumatology (Oxford). 2011. PMID: 21672969
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J. Braun J, et al. Among authors: sorensen h. Arthritis Rheum. 2003 Aug;48(8):2224-33. doi: 10.1002/art.11104. Arthritis Rheum. 2003. PMID: 12905476 Free article. Clinical Trial.
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J. Braun J, et al. Among authors: sorensen h. Rheumatology (Oxford). 2005 May;44(5):670-6. doi: 10.1093/rheumatology/keh584. Epub 2005 Mar 9. Rheumatology (Oxford). 2005. PMID: 15757965 Clinical Trial.
2,582 results